Study suggests another look at common treatments for hemophilia

Posted by on June 13, 2016 3:18 pm
Categories: health

Participants who received a recombinant therapy— the present standard in the United States — developed antibodies or “inhibitors” to the treatments at almost twice the rate as those whose treatments were made from human plasma, new research shows.

Leave a Reply

Your email address will not be published. Required fields are marked *